Last reviewed · How we verify
NCT04634097
DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI)
NA trial testing Experimental group in Cancer Patients With Cancer Pain in 246 participants. Completed in 3 September 2024.
3 September 2024
Quick facts
| Lead sponsor | Institut Curie |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 246 |
| Start date | 5 March 2021 |
| Primary completion | 3 September 2024 |
| Estimated completion | 3 September 2024 |
| Sites | 5 locations across France |
Drugs / interventions tested
- Experimental group
- standrad group
Conditions studied
- Cancer Patients With Cancer Pain — all drugs for Cancer Patients With Cancer Pain →
Sponsor
Institut Curie — full company profile →
Who can join
18 and older, any sex, with Cancer Patients With Cancer Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cancer pain is a frequent symptom, reported by 20 to 70% of patients in any stage of the cancer disease : 60 to 70% in the advanced stage of the disease and 20 to 40% among the survivors. Among patients who report pain, 40% report undertreated pain. Strengthening Pain management in cancer is a specific objective of the French Cancer Plan. Providing patient education for cancer pain management is recommended since small to moderate efficacy of patient education on pain intensity and interference was found in all meta-analysis. An effect size comparable with some analgesic agents. However, recommendations suggest improvement in order to increase effectiveness and population reach of those interventions. The DECLIC EPRI intervention aim at addressing all the issues raised by patient education for cancer pain management. It was developed according to the framework of Michie's Behavior change wheel theory.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04634097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Experimental group
Trials testing the same drug.
- NCT07473076 — REgulating Pain Through Neurofeedback in infLammatory Bowel diseasE and Musculoskeletal Dysfunction · NA · not yet recruiting
- NCT06837831 — Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin · NA · recruiting
- NCT07055945 — Investigation of the Effects of Visual-Motor Based Training on Upper Extremity Functions in Individuals With Stroke · NA · recruiting
- NCT06907927 — Using Artificial Intelligence to Improve Radiologists' Performance in Radiology Report Writing: a Randomised Controlled · NA · recruiting
- NCT06832345 — The Effect of Web-Based Training and Counseling Given to Caregivers on the Pressure Injury Risk, Level of Dependence-Ind · NA · not yet recruiting
Other Institut Curie trials
Trials by the same sponsor.
- NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
- NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
- NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
- NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04634097 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Curie
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04634097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing